Clinical trial
Stereotactic Body Radiotherapy and NALIRIFOX for Locally Advanced Pancreatic Cancer: A Prospective Clinical Trial
NCT07173387 is registered in ClinicalTrials.gov with Shandong Cancer Hospital and Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Stereotactic Body Radiotherapy and NALIRIFOX for Locally Advanced Pancreatic Cancer: A Prospective Clinical Trial
- Lead sponsor
- Shandong Cancer Hospital and Institute
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- October 1, 2025
- Completion date
- December 31, 2028
- Enrollment
- 42 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
pancreatic cancer